IMI International Medical Innovations Retains New York-Based Investor Relations Firm

IMI International Medical Innovations Retains New York-Based
Investor Relations Firm 


TORONTO, Aug. 31  /PRNewswire-FirstCall/ -- IMI International Medical
Innovations Inc. (TSX: IMI, Amex: IME), a leader in predictive medicine, has
engaged The Investor Relations Group, Inc. (IRG), based in New York City, to
serve as its financial relations and corporate communications company.

IRG will strive to increase investor awareness of IMI within the U.S. market by
individually and personally introducing IMI and its management to pre-qualified
fund managers. IRG will also focus on increasing public awareness of IMI and
its non-invasive tests for the early detection of life-threatening diseases, by
providing an extensive array of public relations services, including obtaining
media placement in television, radio, magazine, newspaper and trade media
outlets.

"Commercialization of IMI's first product, PREVU(x) Coronary Heart Disease
Predictor, is advancing, and we are building strong momentum with our portfolio
of cancer detection tests," said Dr. Brent Norton, President and CEO of IMI.
"In line with this progress, management is focused on maximizing shareholder
value. A key component of this effort will be to increase investor and public
awareness of IMI's growth potential and unique platform of non-invasive,
predictive tests for early-stage heart disease and colorectal, lung and breast
cancers. We look forward to working with the IRG team to achieve this goal."

In the future, all U.S. investor inquiries relating to IMI should be directed
to The Investor Relations Group, New York, N.Y., Telephone: [phone], Fax:
212.825.3229, Email: .

About IMI

IMI is a world leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening diseases. IMI's
cardiovascular products, which are branded as PREVU(x) Coronary Heart Disease
Predictor, will be marketed and distributed worldwide by McNeil Consumer
Healthcare. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM)
and a breast cancer test. IMI's head office is located in Toronto, and its
research and product development facility is at McMaster University in
Hamilton, Ontario. For further information, please visit
http://www.imimedical.com/.

About The Investor Relations Group

The Investor Relations Group, Inc., (IRG) founded in 1996, represents select
publicly traded companies, with a unique specialization for assisting those in
the small-cap sector. IRG arranges one-on-one meetings for its portfolio
companies with pre-qualified money managers handling investment portfolios that
range from $10 million to $10 billion+ selected from its proprietary contact
base of over 33,000 qualified fund managers who have an investing history in
small cap stocks. IRG is a full-service corporate communications company
offering services for its portfolio companies that include writing all press
releases and shareholder communications and serving as primary contact for the
investing community. IRG also houses a full-service public relations arm that
specializes in building awareness of its companies within the financial and
trade media, as well as the public at large. For further information, please
visit the company's website at http://www.investorrelationsgroup.com/

This release contains forward-looking statements that reflect the company's
current expectations regarding future events. The forward-looking statements
involve risks and uncertainties. Actual events could differ materially from
those projected herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely completion of
clinical studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to time
in the company's quarterly, annual and other regular filings. 

DATASOURCE: IMI International Medical Innovations Inc.



CONTACT: Company Contact: Sarah Borg-Olivier, Director, Communications,

IMI International Medical Innovations Inc., [phone]; Investor Relations

Contact: Jane Lin/John Nesbett, The Investor Relations Group, [phone]

Copyright